Using Genetic Polymorphisms of Drug Metabolism and Immunohistochemical Stain to Predict the Efficacy and Toxicity in Patients With Gastric Adenocarcinoma - A Phase II Study

Trial Profile

Using Genetic Polymorphisms of Drug Metabolism and Immunohistochemical Stain to Predict the Efficacy and Toxicity in Patients With Gastric Adenocarcinoma - A Phase II Study

Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 May 2016

At a glance

  • Drugs Capecitabine (Primary) ; Docetaxel (Primary) ; Oxaliplatin (Primary) ; Cisplatin
  • Indications Adenocarcinoma; Gastric cancer
  • Focus Biomarker; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 03 May 2016 Status changed from recruiting to discontinued due to budget issues.
    • 29 Oct 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
    • 26 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top